Research ExplorerPublicationsDoxorubicin: effect of different schedules on toxicity and a...

Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy.

Standard

Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. / Bielack, S S; Erttmann, Rudolf; Winkler, K; Landbeck, G.

In: Eur J Cancer Clin Oncol, Vol. 25, No. 5, 5, 1989, p. 873-882.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Bielack, SS, Erttmann, R, Winkler, K & Landbeck, G 1989, 'Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy.', Eur J Cancer Clin Oncol, vol. 25, no. 5, 5, pp. 873-882. <http://www.ncbi.nlm.nih.gov/pubmed/2661240?dopt=Citation>

APA

Bielack, S. S., Erttmann, R., Winkler, K., & Landbeck, G. (1989). Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol, 25(5), 873-882. [5]. http://www.ncbi.nlm.nih.gov/pubmed/2661240?dopt=Citation

Vancouver

Bielack SS, Erttmann R, Winkler K, Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol. 1989;25(5):873-882. 5.

Bibtex

@article{08d4f06cfabd4b05b2649d13a4e24c08,
title = "Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy.",
abstract = "The risk of congestive heart failure restricts the clinical use of doxorubicin to cumulative doses of 450-550 mg/m2, when it is given using high-dose rapid intravenous application. As the high peak serum levels which follow rapid administration seem to be correlated with cardiotoxicity, application schedules leading to lower peak serum concentrations have been developed. This paper reviews the influence of those schedules on cardiotoxicity, non-cardiac toxicities, pharmacokinetic data and antineoplastic efficacy. While the reduction of cardiotoxicity by long-term application schedules is well documented, much less can be said about the antitumor effect of those schedules. Controlled studies dealing with this problem are needed. This review provides a base for that purpose.",
author = "Bielack, {S S} and Rudolf Erttmann and K Winkler and G Landbeck",
year = "1989",
language = "Deutsch",
volume = "25",
pages = "873--882",
number = "5",

}

RIS

TY - JOUR

T1 - Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy.

AU - Bielack, S S

AU - Erttmann, Rudolf

AU - Winkler, K

AU - Landbeck, G

PY - 1989

Y1 - 1989

N2 - The risk of congestive heart failure restricts the clinical use of doxorubicin to cumulative doses of 450-550 mg/m2, when it is given using high-dose rapid intravenous application. As the high peak serum levels which follow rapid administration seem to be correlated with cardiotoxicity, application schedules leading to lower peak serum concentrations have been developed. This paper reviews the influence of those schedules on cardiotoxicity, non-cardiac toxicities, pharmacokinetic data and antineoplastic efficacy. While the reduction of cardiotoxicity by long-term application schedules is well documented, much less can be said about the antitumor effect of those schedules. Controlled studies dealing with this problem are needed. This review provides a base for that purpose.

AB - The risk of congestive heart failure restricts the clinical use of doxorubicin to cumulative doses of 450-550 mg/m2, when it is given using high-dose rapid intravenous application. As the high peak serum levels which follow rapid administration seem to be correlated with cardiotoxicity, application schedules leading to lower peak serum concentrations have been developed. This paper reviews the influence of those schedules on cardiotoxicity, non-cardiac toxicities, pharmacokinetic data and antineoplastic efficacy. While the reduction of cardiotoxicity by long-term application schedules is well documented, much less can be said about the antitumor effect of those schedules. Controlled studies dealing with this problem are needed. This review provides a base for that purpose.

M3 - SCORING: Zeitschriftenaufsatz

VL - 25

SP - 873

EP - 882

IS - 5

M1 - 5

ER -